Acurx Pharmaceuticals (ACXP) EPS (Basic) (2024 - 2026)

Acurx Pharmaceuticals (ACXP) has 3 years of EPS (Basic) data on file, last reported at -$0.62 in Q1 2026.

• Quarterly EPS (Basic) rose 71.17% year-over-year to -$0.62 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.76 (up 77.03% YoY) and the FY2025 annual result came in at -$5.32, up 69.87% from the prior year.
• EPS (Basic) improved to -$0.62 in Q1 2026, from -$1.05 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of -$0.62 in Q1 2026 to a low of -$5.21 in Q2 2024.
• A 3-year average of -$2.4 and a median of -$2.02 in 2025 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2025 — EPS (Basic) jumped 63.77% — and 2026, when it surged 71.17%.
• Tracing ACXP's EPS (Basic) over 3 years: stood at -$3.63 in 2024, then soared by 71.02% to -$1.05 in 2025, then soared by 41.28% to -$0.62 in 2026.
• The last three EPS (Basic) figures came in at -$0.62 (Q1 2026), -$1.05 (Q4 2025), and -$1.23 (Q3 2025), per Business Quant data.